Antibody targeting ‘do not eat me’ signals is active in AML, MDSJune 11, 2019AMLMyelodysplastic SyndromeLeukemia, Myelodysplasia, Transplantation
Combo produces ‘best response rate’ after first relapse in kids with AMLJune 1, 2019AMLPediatricsLeukemia, Myelodysplasia, Transplantation
FDA panel not ready to recommend quizartinib approval for FLT3-ITD+ AMLMay 14, 2019AMLLeukemia, Myelodysplasia, Transplantation
Master trial seeks to aid drug development for pediatric AMLMay 12, 2019AMLLeukemia, Myelodysplasia, TransplantationPediatrics
Researchers propose new risk groups for NK-AMLMay 8, 2019AMLLeukemia, Myelodysplasia, Transplantation
Combo proves most effective in HMA-naive, higher-risk MDSMay 3, 2019Myelodysplastic SyndromeLeukemia, Myelodysplasia, TransplantationAML
FDA approves ivosidenib frontline for certain AML patientsMay 3, 2019AMLLeukemia, Myelodysplasia, Transplantation
Sorafenib plus GCLAM held safe in AML, MDS phase-1 studyApril 22, 2019Leukemia, Myelodysplasia, TransplantationAMLMyelodysplastic Syndrome
Study highlights lack of data on transgender leukemia patientsApril 19, 2019AMLLeukemia, Myelodysplasia, Transplantation
ALF 2019 showcases evolving treatment of AMLApril 19, 2019AMLLeukemia, Myelodysplasia, TransplantationTransplantation
Back to the drawing board for MPN comboApril 18, 2019Leukemia, Myelodysplasia, TransplantationCythemiasAML
Whole-genome sequencing demonstrates clinical relevanceApril 4, 2019AMLALLLeukemia, Myelodysplasia, Transplantation
Secondary AML in first remission predicts outcomesMarch 14, 2019TransplantationLeukemia, Myelodysplasia, TransplantationAML
Anti-CD45 conditioning looks safe, feasible in relapsed AMLMarch 13, 2019TransplantationAMLLeukemia, Myelodysplasia, Transplantation
